DOP44: Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRNECCO'21 VirtualYear: 2021
Authors: Magen Rimon, R.(1);Atia, O.(2);Friss, C.(2);Ledderman, N.(3);Greenfeld, S.(4);Kariv, R.(4);Loewenberg Weisband, Y.(5);Gabay, C.(5);Shaoul, R.(1);Odes, S.(6);Matz, E.(7);Dotan, I.(8);Turner, D.(2)
(1)Rambam Medical Center, Pediatric Gastroenterology & Nutrition institute, Haifa, Israel;(2)Shaare Zedek Medical Center, Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(3)Meuhedet Health Services, Meuhedet Health Services, Tel Aviv, Israel;(4)Maccabi Health Services, Maccabi Health Services, Tel Aviv, Israel;(5)Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel;(6)Ben-Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel;(7)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(8)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel
DOP45: Utilization and sustainability of biologics in CD - A nationwide study from the epi-IIRNECCO'21 VirtualYear: 2021
Authors: Atia, O.(1); Yogev, D.(1);Chagit, F.(1);Gili, F.(1); Orlanski-Meyer, E.(1);Magen Rimon, R.(2);Natan, L.(3);Shira, G.(4); Kariv, R.(4);Yisca, L.W.(5); Gabay, H.(5); Nevo, D.(6); Matz, E.(7); Gorelik, Y.(8); Chowers, Y.(8);Iris, D.(9);Turner, D.(1)
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Israel., Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Pediatric Gastroenterology & Nutrition institute- Ruth Rappaport Children's Hospital- Rambam Medical Center, Faculty of Medicine- Technion, Haifa, Israel;(3)Meuhedet Health Services, Meuhedet Health Services, Tel-Aviv, Israel;(4)Maccabi Health Services, The Sackler Faculty of Medicine- Tel Aviv University- Israel., Tel-Aviv, Israel;(5)Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel;(6)Department of Statistics and Operations Research, Tel Aviv University- Israel, Tel Aviv, Israel;(7)Leumit Health Services, Leumit Health Services, Tel-Aviv, Israel;(8)Technion Israel Institute of Technology- Department of Gastroenterology, Rambam Healthcare Campus- Bruce Rappaport School of Medicine, Haifa, Israel;(9)Division of Gastroenterology- Rabin Medical Center, The Sackler Faculty of Medicine- Tel Aviv University- Israel, Petah Tikva, Israel
DOP46: Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohortECCO'21 VirtualYear: 2021
Authors: Atia, O.(1); Friss, C.(1);Mendelovici, A.(1); Shteyer, E.(1); Yogev, D.(1);Ledderman, N.(2); Greenfeld, S.(3); Kariv, R.(3); Loewenberg Weisband, Y.(4); Gabay, H.(4); Nevo, D.(5); Matz, E.(6); Dotan, I.(7);Turner, D.(1)
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Israel., Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Meuhedet Health Services, Meuhedet Health Services, Tel-Aviv, Israel;(3)Maccabi Health Services-, he Sackler Faculty of Medicine- Tel Aviv University- Israel., Tel Aviv, Israel;(4)Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel;(5)Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel;(6)Leumit Health Services-, . Leumit Health Services, Tel-Aviv, Israel;(7)Division of Gastroenterology- Rabin Medical Center, the Sackler Faculty of Medicine- Tel Aviv University- Israel., Petah Tikva, Israel
DOP47: Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD StudyECCO'21 VirtualYear: 2021
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);Di Giuseppe, R.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atreya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann , P.(1);Schreiber, S.(13)
(1)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis, Minden, Germany;(2)Kompetenznetz Darmerkrankungen e.V., Abteilung Studien, Kiel, Germany;(3)Kompetenznetz Darmerkrankungen e.V., Epidemiology and Biometry, Kiel, Germany;(4)Gastroenterology Practice, Innere Medizin- Gastroenterologie- Ärztliches Qualitätsmanagement, Saarbrücken, Germany;(5)Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselerkrankungen, Innere Medizin- Gastroenterologie- Hepatologie- Proktologie, Münster, Germany;(6)Gastroenterology Practice, Medizinisches Versorgungszentrum, Iserlohn, Germany;(7)Gastroenterologische Gemeinschaftspraxis, Innere Medizin- Gastroenterologie- Hepatologie- Proktologie, Münster, Germany;(8)Gastroenterologische Gemeinschaftspraxis Herne, Gastroenterologische, Herne, Germany;(9)University Hospital Heidelberg, Department of Gastroenterology and Hepatology, Heidelberg, Germany;(10)Universitätsklinikum Erlangen, Innere Medizin, Erlangen, Germany;(11)Gastroenterological practice, Gastroenterology, Kassel, Germany;(12)Goethe-Universität Frankfurt am Main, Innere Medizin- Gastroenterologie- Ernährungsmedizin, Frankfurt am Main, Germany;(13)Universitätsklinikum Schleswig-Holstein UKSH, Klinik für Innere Medizin I, Kiel, Germany
DOP49: Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-GroupECCO'21 VirtualYear: 2021
Authors: Pugliese, D.(1);Privitera, G.(2);Armuzzi, A.(3)
(1)Fondazione Policlinico Universitario Agostino Gemelli IRCCS, CEMAD-IBD UNIT- Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Rome, Italy;(2)Università Cattolica del Sacro Cuore, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Rome, Italy;(3)Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica, CEMAD - IBD Unit- Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Rome, Italy; LIVE STUDY GROUP
DOP50: Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Ledder, O.(1);Lujan, R.(1);Orlanski-Meyer, E.(1);Friss, C.(1);Loewenberg Weisband, Y.(2);Greenfeld, S.(3);Kariv, R.(3);Lederman, N.(4);Matz, E.(5);Focht, G.(1);Yanai, H.(6);Ollech, Y.(6);Dotan, I.(6);Turner, D.(1)
(1)Shaare Zedek Medical Center, Department of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel;(3)Maccabi Healthcare Services, Maccabi Healthcare Services, Tel Aviv, Israel;(4)Meuhedet Health Services, Meuhedet Health ServicesTel, Tel Aviv, Israel;(5)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(6)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel
DOP51: De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalationECCO'21 VirtualYear: 2021
Authors: Thomas, P.(1);Smits, L.(1);Te Groen, M.(1);West, R.(2);Russel, M.(3);Jansen, J.(4);Römkens, T.(5);Hoentjen, F.(1)
(1)Radboudumc, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Franciscus Gasthuis & Vlietland, Gastroenterology and Hepatology, Rotterdam, The Netherlands;(3)Medisch Spectrum Twente, Gastroenterology and Hepatology, Enschede, The Netherlands;(4)Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Jeroen Bosch Ziekenhuis, Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands
DOP52: Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)ECCO'21 VirtualYear: 2021
Authors: Chaparro, M.(1);García Donday, M.(1);Calviño Suarez, C.(2);Rubio, S.(3);Figueira, M.(4);Pérez Martínez, I.(5);Leo Carnerero, E.(6);Rodríguez Lago, I.(7);Ruiz Cerulla, A.(8);Aguas, M.(9);López Serrano, P.(10);Ramírez de la Piscina Urraca, P.(11);Rivero, M.(12);Suarez Ferrer, C.(13);Alfambra Cabrejas, E.(14);Armesto, R.(15);Diz-Lois Palomares, M.T.(16);Guerra, I.(17); Vázquez Morón, J.M.(18); Casanova, M.J.(1);Hervías Cruz, D.(19); Huguet, J.M.(20); de Jorge Turrión, M.Á.(21); Marín Pedrosa, S.(22);Molina Arriero, G.(23);Ramos, L.(24);Zúñiga de Mora-Figueroa, B.(25);Camargo Camero, R.(26);Fernández-Clotet, A.(27);Gutiérrez Casbas, A.(28);Martínez Montiel, P.(29);Rodríguez Insa, R.(30);Sendra Rumbeu, P.(31);Tardillo Marín, C.(32);Vicente Lidón, R.(33);Arias García, L.(34);Bujanda, L.(35);Lucendo, A.J.(36);Manceñido Marcos, N.(37);Gisbert, J.P.(1)
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(3)Complejo Hospitalario Universitario de Navarra, Gastroenterology Unit, Pamplona, Spain;(4)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(5)Hospital Universitario Central de Asturias e Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(6)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(7)Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(8)Hospital Universitario de Bellvitge, Gastroenterology Unit, Barcelona, Spain;(9)Hospital Universitario y Politécnico La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain;(10)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(11)Hospital Universitario de Álava, Gastroenterology Unit, Álava, Spain;(12)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(13)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(14)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(15)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(16)Complexo Hospitalario Universitario de A Coruña, Gastroenterology Unit, A Coruña, Spain;(17)Hospital Universitario de Fuenlabrada e Instituto de Investigación Hospital Universitario La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain;(18)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(19)Hospital General Universitario de Cuidad Real, Gastroenterology Unit, Cuidad Real, Spain;(20)Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(21)Hospital Universitario de Cabueñes, Gastroenterology Unit, Gijón, Spain;(22)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(23)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(24)Hospital Universitario de Canarias, Gastroenterology Unit, Tenerife, Spain;(25)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(26)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(27)Hospital Universitario Clìnic i Provincial and CIBEREHD, Gastroenterology Unit, Barcelona, Spain;(28)Hospital General Universitario de Alicante- CIBERehd and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Gastroenterology Unit, Alicante, Spain;(29)Hospital Universitario 12 de Octubre, Gastroenterology Unit, Madrid, Spain;(30)Hospital General Universitario de Castellón, Gastroenterology Unit, Castellón, Spain;(31)Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(32)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology Unit, Tenerife, Spain;(33)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(34)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(35)Instituto Biodonostia- Universidad del País Vasco UPV/EHU y CIBEREHD, Gastroenterology Unit, Guipúzcoa, Spain;(36)Hospital General de Tomelloso. Instituto de Investigación Sanitaria Princesa IIS-IP. CIBEREHD, Gastroenterology Unit, Ciudad Real, Spain;(37)Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain; on behalf of DUMBO study group
DOP53: Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Dubinsky, M.C.(1);Mahadevan, U.(2);Charles, L.(3);Afsari, S.(3);Henry, A.(3);Comi, G.(4);Selmaj, K.(5);van der Woude, C.J.(6)
(1)Icahn School of Medicine, Pediatrics- Gastroenterology, Mount Sinai, United States;(2)University of California San Francisco, Gastroenterology, San Francisco, United States;(3)Bristol Myers Squibb, Global Drug Safety & Risk Mgmt, Princeton, United States;(4)San Raffaele Scientific Institute- Vita-Salute San Raffaele University, Department of Neurology, Milan, Italy;(5)Center for Neurology- Łódź- Poland and Collegium Medicum- University of Warmia and Mazury, Department of Neurology, Olsztyn, Poland;(6)Erasmus MC, Gastroenterology, Rotterdam, Netherlands Antilles
DOP54: Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?ECCO'21 VirtualYear: 2021
Authors: Rezazadeh Ardabili, A.(1,2);Jeuring, S.F.G.(1);Mujagic, Z.(1,2);Romberg-Camps, M.J.L.(3);van Bodegraven, A.A.(3);Jonkers, D.M.A.E.(1,2);Pierik, M.J.(1,2)
(1)Department of Internal Medicine- Division of Gastroenterology, Maastricht University Medical Centre+, Maastricht, The Netherlands;(2)School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands;(3)Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands
DOP55: Histopathological features at diagnosis to predict long-term disease course of Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Rezazadeh Ardabili, A.(1,2);Goudkade, D.(3);Wintjens, D.S.J.(1,2);Romberg-Camps, M.J.L.(4);Winkens, B.(5);Pierik, M.J.(1,2);Grabsch, H.I.(6,7);Jonkers, D.M.A.E.(1,2)
(1)Department of Internal Medicine- Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands;(2)School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands;(3)Department of Pathology, Zuyderland Medical Centre, Geleen, The Netherlands;(4)Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands;(5)Department of Methodology and Statistics- Care and Public Health Research Institute CAPHRI, Maastricht University, Maastricht, The Netherlands;(6)Department of Pathology- GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands;(7)Division of Pathology & Data Analytics- Lees Institute of Medical Research at St. James's, Univeristy of Leeds, Leeds, United Kingdom
DOP57: Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Maruszczak, M.(1);Genenz, K.(2);Turkstra, E.(3);Fenu, E.(2);Hantsbarger, G.(4);Gilaberte, I.(5);Karki, C.(6);Panes, J.(7)
(1)Parexel International, Data Analytics and Machine Learning, Uxbridge, United Kingdom;(2)Takeda Pharmaceuticals, Takeda Pharmaceuticals, Zurich, Switzerland;(3)Parexel International, Parexel Access Consulting, Uxbridge, United Kingdom;(4)Takeda Pharmaceuticals USA- Inc, Statistical and Quantitative Sciences, Cambridge, United States;(5)Takeda Pharmaceuticals USA- Inc, Clinical Sciences, Cambridge, United States;(6)Takeda Pharmaceuticals USA- Inc, Global Evidence and Outcomes, Cambridge, United States;(7)Hospital Clínic de Barcelona- IDIBAPS, Gastroenterology Department, Barcelona, Spain
DOP58: Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trialsECCO'21 VirtualYear: 2021
Authors: Greywoode, R.(1);Petralia, F.(2);Ullman, T.(1);Colombel, J.F.(3);Ungaro, R.(3)
(1)Montefiore Medical Center, Division of Gastroenterology, Bronx, United States;(2)Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States
DOP59: Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscoreECCO'21 VirtualYear: 2021
Authors: Lee, S.D.(1);Allegretti, J.R.(2);Steinwurz, F.(3);Connelly, S.B.(4);Lawendy, N.(4);Paulissen, J.(5);Gecse, K.B.(6)
(1)Digestive Health Center, University of Washington Medical Center, Seattle- Washington, United States;(2)Division of Gastroenterology- Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston- Massachusetts, United States;(3)Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil;(4)Pfizer Inc, Collegeville, Pennsylvania, United States;(5)Pfizer Inc, New York, New York, United States;(6)Amsterdam UMC, Amsterdam, The Netherlands
DOP60: Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study dataECCO'21 VirtualYear: 2021
Authors: Mantzaris, G.(1);Yarur, A.(2);Wang, S.(3);Adsul, S.(4);Kamble, P.(4);Luo, M.(3);Guerin, A.(5);Billmyer, E.(5);Nguyen, H.(5);Bressler, B.(6)
(1)Evangelismos Hospital, Department of Gastroenterology, Athens, Greece;(2)Medical College of Wisconsin, Department of Gastroenterology, Milwaukee, United States;(3)Takeda Pharmaceuticals, Takeda, Cambridge, United States;(4)Takeda Pharmaceuticals-, Takeda, Cambridge, United States;(5)Analysis Group, Analysis Group, Boston, United States;(6)St. Paul’s Hospital, Division of Gastroenterology- Department of Medicine, Vancouver, Canada
DOP61: Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING studyECCO'21 VirtualYear: 2021
Authors: Sandborn, W.J.(1);Dubinsky, M.C.(2);Torres, J.(3);Vermeire, S.(4);Kotze, P.G.(5);Su, C.(6);Lawendy, N.(6);Paulissen, J.(7);Mundayat, R.(7);Gardiner, S.(7);Kulisek, N.(6);Modesto, I.(7);D’Haens, G.R.(8)
(1)Division of Gastroenterology, University of California, San Diego- La Jolla- California, United States;(2)Icahn School of Medicine at Mount Sinai, New York, New York, United States;(3)Surgical Department- Gastroenterology Division, Hospital Beatriz Ângelo- Loures, and Faculdade de Medicina- Universidade de Lisboa- Lisbon, Portugal;(4)Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium;(5)IBD Outpatient Clinics- Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands
DOP62: Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapyECCO'21 VirtualYear: 2021
Authors: Chanchlani, N.(1);Lin, S.(1);Thomas, A.(1);Hamilton, B.(1);Nice, R.(2);Chee, D.(1);Kennedy, N.(1);Goodhand, J.(1);Ahmad, T.(1)
(1)Exeter IBD Pharmacogenetics, Gastroenterology, Exeter, United Kingdom;(2)Exeter Clinical Laboratory International, Biochemistry, Exeter, United Kingdom IMSAT study investigators
DOP63: The Toronto IBD global endoscopic reporting (TIGER) score is well correlated with fecal calprotectin and IBD Disk in Ulcerative Colitis patientsECCO'21 VirtualYear: 2021
Authors: Zittan, E.(1,2);Steinhart, A.H.(3); Aran, H.(1);Milgrom, R.(3); Koifman, E.(1);Gralnek, I.M.(1); Zelber-Sagi, S.(2); Silverberg, M.S.(3)
(1)Emek Medical Center, Ellen and Pinchas Mamber Institute of Gastroenterology and Liver Diseases- IBD Unit, Afula, Israel;(2)University of Haifa, School of Public Health- Faculty of Social Welfare and Health Sciences, Haifa, Israel;(3)Mount Sinai Hospital- Zane Cohen Centre for Digestive Diseases- University of Toronto, Division of Gastroenterology- Department of Medicine, Toronto, Canada
